Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 1/20 | 0.46 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.46 |
| ▸ | MTOR | P42345 | 17/20 | 0.43 |
| ▸ | PIK3CA | P42336 | 14/20 | 0.39 |
| ▸ | PIK3R1 | P27986 | 9/20 | 0.39 |
| ▸ | RICTOR | Q6R327 | 9/20 | 0.39 |
| ▸ | RPTOR | Q8N122 | 9/20 | 0.39 |
| ▸ | MAPKAP1 | Q9BPZ7 | 9/20 | 0.39 |
| ▸ | MLST8 | Q9BVC4 | 9/20 | 0.39 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.36 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.35 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.35 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.35 |
| ▸ | PIK3C3 | Q8NEB9 | 2/20 | 0.35 |
| ▸ | MAP3K12 | Q12852 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17796315 | 0.90 | MTOR (0.46) | CHRNB2CHRNA4MTORPIK3CAPIK3R1 | |
| SCHEMBL24374902 | 0.90 | CHRNB2 (0.44) | CHRNB2CHRNA4MTORPIK3CAPIK3R1 | |
| SCHEMBL17108491 | 0.80 | MTOR (0.44) | CHRNB2CHRNA4MTORPIK3CAPIK3R1 | |
| SCHEMBL17108489 | 0.80 | MTOR (0.44) | CHRNB2CHRNA4MTORPIK3CAPIK3R1 | |
| SCHEMBL30316567 | 0.80 | MTOR (0.44) | CHRNB2CHRNA4MTORPIK3CAPIK3R1 | |
| SCHEMBL30315969 | 0.80 | MTOR (0.44) | CHRNB2CHRNA4MTORPIK3CAPIK3R1 | |
| SCHEMBL24374898 | 0.78 | CHRNB2 (0.51) | CHRNB2CHRNA4MTORPIK3CAPIK3R1 | |
| SCHEMBL14916061 | 0.76 | CHRNB2 (0.43) | CHRNB2CHRNA4MTORPIK3CAPIK3R1 | |
| SCHEMBL14916901 | 0.76 | PIK3CA (0.50) | CHRNB2CHRNA4MTORPIK3CAPIK3R1 | |
| SCHEMBL23089116 | 0.75 | CHRNB2 (0.44) | CHRNB2CHRNA4MTORPIK3CAMAP3K12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4019518-A1 | TYK2 INHIBITORS AND USES THEREOF | Nimbus Lakshmi, Inc. (US) | 2022-06-29 | — | — | EP | disclosed |
| EP-3110820-B1 | TYK2 INHIBITORS AND USES THEREOF | NIMBUS LAKSHMI INC (US) | 2022-04-06 | — | — | EP | disclosed |
| US-10196390-B2 | TYK2 inhibitors and uses thereof | NIMBUS LAKSHMI, INC. (US) | 2019-02-05 | — | — | US | disclosed |
| US-20170247373-A1 | TYK2 INHIBITORS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-08-31 | — | — | US | disclosed |
| US-20170247373-A1 | TYK2 INHIBITORS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-08-31 | — | — | US | disclosed |
| US-9630970-B2 | TYK2 inhibitors and uses thereof | NIMBUS LAKSHMI, INC. (US) | 2017-04-25 | — | — | US | disclosed |
| US-9630970-B2 | TYK2 inhibitors and uses thereof | NIMBUS LAKSHMI, INC. (US) | 2017-04-25 | — | — | US | disclosed |
| US-20160297826-A1 | TYK2 INHIBITORS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-10-13 | — | — | US | disclosed |
| US-20160297826-A1 | TYK2 INHIBITORS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-10-13 | — | — | US | disclosed |
| US-9340540-B2 | TYK2 inhibitors and uses thereof | NIMBUS LAKSHMI, INC. (US) | 2016-05-17 | — | — | US | disclosed |
| US-9340540-B2 | TYK2 inhibitors and uses thereof | NIMBUS LAKSHMI, INC. (US) | 2016-05-17 | — | — | US | disclosed |
| US-20150266875-A1 | TYK2 INHIBITORS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-09-24 | — | — | US | disclosed |
| US-20150266875-A1 | TYK2 INHIBITORS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-09-24 | — | — | US | disclosed |
| WO-2015131080-A1 | TYK2 INHIBITORS AND USES THEREOF | NIMBUS LAKSHMI, INC. (US) | 2015-09-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10196390-B2 | TYK2 inhibitors and uses thereof | TYK2, JAK2, JAK1 | CHRNB2 3189/4885CHRNA4 4028/4885MTOR 1094/4885 |
| US-20150266875-A1 | TYK2 INHIBITORS AND USES THEREOF | TYK2, JAK2, JAK1 | CHRNB2 3189/4885CHRNA4 4028/4885MTOR 1094/4885 |
| US-20160297826-A1 | TYK2 INHIBITORS AND USES THEREOF | TYK2, JAK2, JAK1 | CHRNB2 3189/4885CHRNA4 4028/4885MTOR 1094/4885 |
| US-20170247373-A1 | TYK2 INHIBITORS AND USES THEREOF | TYK2, JAK2, JAK1 | CHRNB2 3189/4885CHRNA4 4028/4885MTOR 1094/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.